The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Trazimera trastuzumab BiosimilarAdditional monitoring | Pfizer Europe MA EEIG | Stomach Neoplasms; Breast Neoplasms | 🇪🇺 EU 2018-07-26 | Order → |
| Carmustine medac (previously Carmustine Obvius) carmustine Generic | medac Gesellschaft für klinische Spezialpräparate mbH | Hodgkin Disease; Lymphoma, Non-Hodgkin | 🇪🇺 EU 2018-07-18 | Order → |
| Tegsedi inotersen OrphanAccelerated assessment | Akcea Therapeutics Ireland Limited | Amyloidosis | 🇪🇺 EU 2018-07-06 | Order → |
| Verkazia ciclosporin OrphanAccelerated assessment | Santen Oy | Conjunctivitis; Keratitis | 🇪🇺 EU 2018-07-06 | Order → |
| Graspa asparaginase Orphan | ERYTECH Pharma S.A. | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 🇪🇺 EU 2018-06-27 | Order → |
| Dzuveo sufentanil | Laboratoire Aguettant | Pain | 🇪🇺 EU 2018-06-25 | Order → |
| Biktarvy bictegravir;emtricitabine;tenofovir alafenamide | Gilead Sciences Ireland UC | HIV Infections | 🇪🇺 EU 2018-06-21 | Order → |
| Amglidia glibenclamide Orphan | Ammtek | Diabetes Mellitus | 🇪🇺 EU 2018-05-24 | Order → |
| Rubraca rucaparib | pharmaand GmbH | Ovarian Neoplasms | 🇪🇺 EU 2018-05-23 | Order → |
| Pemetrexed Krka pemetrexed Generic | KRKA tovarna zdravil d.d. Novo mesto | Carcinoma, Non-Small-Cell Lung; Mesothelioma | 🇪🇺 EU 2018-05-22 | Order → |
| Zessly infliximab Biosimilar | Sandoz GmbH | Arthritis, Psoriatic; Psoriasis; Crohn Disease; Arthritis, Rheumatoid; Colitis, Ulcerative; Spondylitis, Ankylosing | 🇪🇺 EU 2018-05-18 | Order → |
| Juluca dolutegravir;rilpivirine | ViiV Healthcare B.V. | HIV Infections | 🇪🇺 EU 2018-05-16 | Order → |
| Kanjinti trastuzumab Biosimilar | Amgen Europe B.V. | Stomach Neoplasms; Breast Neoplasms | 🇪🇺 EU 2018-05-16 | Order → |
| Prasugrel Viatris (previously Prasugrel Mylan) prasugrel Generic | Viatris Limited | Myocardial Infarction; Acute Coronary Syndrome; Angina, Unstable | 🇪🇺 EU 2018-05-15 | Order → |
| Trydonis beclometasone;formoterol;glycopyrronium bromide | Chiesi Farmaceutici S.p.A. | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2018-04-26 | Order → |
| Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.) beclometasone;formoterol | Chiesi Farmaceutici S.p.A. | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2018-04-23 | Order → |
| Mylotarg gemtuzumab ozogamicin Orphan | Pfizer Europe MA EEIG | Leukemia, Myeloid, Acute | 🇪🇺 EU 2018-04-19 | Order → |
| Alpivab peramivir Additional monitoring | Biocryst | Influenza, Human | 🇪🇺 EU 2018-04-13 | Order → |
| Alofisel darvadstrocel ATMP | Takeda Pharma A/S | Rectal Fistula | 🇪🇺 EU 2018-03-23 | Order → |
| Lamzede velmanase alfa OrphanExceptional circumstancesAdditional monitoring | Chiesi Farmaceutici S.p.A. | alpha-Mannosidosis | 🇪🇺 EU 2018-03-23 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.